Cognition Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Pittsburgh PA United States (2007)

Organization Overview

First Clinical Trial
2007
NCT00529581
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cognition Pharmaceuticals, LLC | Cognition Therapeutics | Cognition Therapeutics Inc. | Cognition Therapeutics, Inc. | Cognition Therapuetics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognition Disorders (Phase 2)

Cognitive Dysfunction (Phase 2)

Multiple Sclerosis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 6